13F reference period
Q2 2026
Security Snapshot
Atrium Therapeutics, Inc. - COMMON STOCK (RNA) Institutional Ownership
CUSIP: 04965N104
13F Institutional Holders and Ownership History from Q1 2026 to Q3 2026
Institutions Reporting
152
Shares (Excl. Options)
14,330,477
Price
$13.45
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- RNA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 14,330,477
- Total 13F value
- $192,751,999
- Portfolio coverage rank
- 0%
- Share change
- -408,384
- Value change
- -$5,232,289
- Number of holders
- 152
- Shares outstanding
- 17,127,721
- SEC-reported price per share
- $8.28
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- RNA - Atrium Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 04965N104.
- 152 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 160 to 152 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $198,321,325 to $192,751,999.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 152 institutions filings for Q2 2026.
Security key
04965N104
13F reference period
Q2 2026
13F holders
152
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
RNA full holder history
Atrium Therapeutics, Inc. SEC filings
Atrium Therapeutics, Inc. company facts
Atrium Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 04965N104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
RNA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sessa Capital IM, L.P. | 8.8% | $20,055,000 | 1,500,000 | Sessa Capital IM, L.P. | 30 Jun 2026 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 8.6% | $19,693,796 | 1,472,984 | T. Rowe Price Associates, Inc. | 30 Jun 2026 | |||
| BlackRock, Inc. | 6.6% | $15,275,932 | 1,135,757 | BlackRock, Inc. | 30 Jun 2026 |
As of 30 Jun 2026, 152 institutional investors reported holding 14,330,477 shares of Atrium Therapeutics, Inc. - COMMON STOCK (RNA). This represents 84% of the company’s total 17,127,721 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
61%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Sessa Capital IM, L.P. | 8.8% | 1,500,000 | +172% | 0.35% | $20,175,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 8.6% | 1,472,984 | -5.2% | 0% | $19,813,000 |
| BlackRock, Inc. | 8.5% | 1,447,476 | +20% | 0% | $19,468,551 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 730,831 | +17% | 0% | $9,829,677 |
| CRCM LP | 3.7% | 641,539 | 5.7% | $8,628,700 | |
| TIG Advisors, LLC | 3.3% | 561,533 | -7.6% | 0.35% | $7,552,619 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 386,929 | +21% | 0% | $5,205,392 |
| TWO SIGMA INVESTMENTS, LP | 2% | 345,481 | +93% | 0% | $4,646,719 |
| GOLDMAN SACHS GROUP INC | 1.8% | 310,341 | -11% | 0% | $4,174,086 |
| 683 Capital Management, LLC | 1.8% | 300,000 | 0% | 0.37% | $4,035,000 |
| STATE STREET CORP | 1.6% | 271,762 | +5.7% | 0% | $3,655,199 |
| Arbiter Partners Capital Management LLC | 1.5% | 261,288 | +14% | 1.9% | $3,514,324 |
| CANTOR FITZGERALD, L. P. | 1.5% | 256,917 | +9% | 0.07% | $3,455,534 |
| Slotnik Capital, LLC | 1.4% | 237,637 | +31% | 0.89% | $3,196,218 |
| Weiss Asset Management LP | 1.3% | 219,730 | -8.7% | 0.03% | $2,955,368 |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 200,559 | +5.1% | 0% | $2,697,519 |
| Schonfeld Strategic Advisors LLC | 1.2% | 199,158 | +22% | 0.01% | $2,678,673 |
| AQR CAPITAL MANAGEMENT LLC | 1% | 172,235 | 0% | $2,316,561 | |
| NEXPOINT ASSET MANAGEMENT, L.P. | 0.88% | 150,025 | 0% | 0.13% | $2,017,836 |
| Polar Asset Management Partners Inc. | 0.88% | 150,000 | +114% | 0.04% | $2,017,500 |
| Squarepoint Ops LLC | 0.86% | 146,743 | -37% | 0% | $1,973,693 |
| Bracebridge Capital, LLC | 0.81% | 139,239 | 0% | 0.41% | $1,872,765 |
| NOMURA HOLDINGS INC | 0.8% | 137,394 | +0.01% | 0.01% | $1,847,949 |
| Yakira Capital Management, Inc. | 0.78% | 133,047 | +5.1% | 0.53% | $1,789,482 |
| BANK OF AMERICA CORP /DE/ | 0.78% | 132,833 | -2.5% | 0% | $1,786,603 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Headline period
Q2 2026
Rows shown
1-3 of 3